ArticleCell death discovery2026
Redox cycling nitroxide limits cellular iron availability and selectively inhibits iron-sulfur cluster metabolism.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Iron-sulfur clusters (ISCs) are redox active cofactors for essential proteins with diverse functions. We demonstrate that Tempol, a redox cycling nitroxide, limits iron bioavailability in a manner distinct from iron chelators, mainly via its effect on ascorbate and iron redox balance. This non-canonical iron limitation triggers upregulation of IRP2 and HIF1α, proteins whose degradation is ferrous iron-dependent, while disrupting ISC synthesis only in a subset of cell lines. Suppression of ISC synthesis inhibits ISC-dependent enzymes, destabilizes ISC proteins, and reduces cell viability, particularly in cells dependent on ISC protein ACO2. These effects are reversed by the reducing agent ascorbate, a cofactor required for multiple enzymes, such as the HIF1α prolyl hydroxylases. Tempol treatment also inhibits ferroptosis, an oxidative form of cell death catalyzed by reduced iron. These results demonstrate ascorbate and cellular iron redox state are essential in iron homeostasis, which is proposed to underlie pathological conditions from neurodegeneration to cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.